Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
jRCT2080224679Phase 1Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of tocilizumab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by National Cancer Center Hospital East. Primary endpoint: Safety and tolerability of tocilizumab plus gemcitabine/nab-paclitaxel. Started May 2019; status: completed.
02
Drugs
tocilizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080224679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224679.